University of Nevada, Reno   Report issue

Academic/Hospital Phase 3 Phase 4
Founded: Reno NV United States (1874)

Organization Overview

First Clinical Trial
2015
NCT02442817
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Renown Regional Medical Center | University of Nevada, Reno

Active Ingredients

Drugs in Phase 4 Trials (3)

linagliptin (tradjenta) (1 trial)

vancomycin (Vancocin) (1 trial)

varenicline (chantix) (1 trial)

Drugs in Phase 3 Trials (1)

simethicone (IMODIUM) (1 trial)

Drugs in Other Trials (2)

human milk (1 trial)

tobacco (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Clostridium Infections (Phase 4)

Communicable Diseases (Phase 4)

Infections (Phase 4)

Schizophrenia (Phase 4)

Substance Withdrawal Syndrome (Phase 4)

Tobacco Use Disorder (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 6